Journal of Neural Transmission

, Volume 116, Issue 2, pp 179–191

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

  • Malcolm Steiger
  • W. Jost
  • F. Grandas
  • G. Van Camp
Parkinson's Disease and Allied Conditions - Review Article


A literature review was conducted to assess risk of cardiac valve regurgitation (CVR) associated with use of ergot-derived and non-ergot dopamine agonists (DAs) in patients with Parkinson’s disease (PD). Inclusion criteria: case-control/observational studies of >10 patients with PD treated with DAs, including a control group and assessment of incidence/risk of CVR. Of the 166 publications identified, 14 met all inclusion criteria and included 1,750 patients. In 11 of the studies, a significant increase in CVR frequency of any severity (at the aortic, mitral or tricuspid valve) in the ergot group vs. the non-ergot or control group was described. No study reported increased risk of CVR for non-ergot DAs, compared with controls. In the studies identified in the literature, the use of ergot-derived DAs (pergolide and cabergoline) in patients with PD was associated with increased risk of CVR. Increased risk of CVR was not associated with the use of non-ergot DAs.


Cardiac valve regurgitation Parkinson’s disease Dopamine agonists Valvular heart disease 


  1. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad, JP, Bertoni et al (1997) Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49:393–399 Google Scholar
  2. Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamine agonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829PubMedCrossRefGoogle Scholar
  3. Bana DS, MacNeal PS, LeCompte PM, Shah Y, Graham JR (1974) Cardiac murmurs and endocardial fibrosis associated with methysergide therapy. Am Heart J 88:640–655PubMedCrossRefGoogle Scholar
  4. Baseman DG, O’Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr (2004) Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 63:301–304PubMedGoogle Scholar
  5. Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F (2002) A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by l-dopa. J Neural Transm 109:489–502PubMedCrossRefGoogle Scholar
  6. Calomne V, Dupuis MJ, Muller T, Kempinere F (2004) Reversible cardiac valve abnormalities with pergolide treatment. Rev Neurol (Paris) 160:81–82Google Scholar
  7. Clarke CE, Guttman M (2002) Dopamine agonist monotherapy in Parkinson’s disease. Lancet 360:1767–1769PubMedCrossRefGoogle Scholar
  8. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD et al (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337:581–588PubMedCrossRefGoogle Scholar
  9. Corvol J-C, Anzouan-Kacou J-B, Fauveau E, Bonnet A-M, Lebrun-Vignes B, Girault C et al (2007) Heart valve regurgitation, pergolide use, and Parkinson disease. Arch Neurol 64:1721–1726PubMedCrossRefGoogle Scholar
  10. Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 276:374–379PubMedGoogle Scholar
  11. Davey Smith G, Egger M (1998) Meta-analysis. Unresolved issues and future developments. BMJ 316:221–225PubMedGoogle Scholar
  12. Dewey RBII, Reimold SC, O’Suilleabhain PE (2007) Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 64:377–380PubMedCrossRefGoogle Scholar
  13. Dhawan V, Medcalf P, Stegie F, Jackson G, Basu S, Luce P et al (2005) Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson’s disease patients treated with cabergoline. J Neural Transm 112:661–668PubMedCrossRefGoogle Scholar
  14. Egger M, Smith GD (1998) Bias in location and selection of studies. BMJ 316:61–66PubMedGoogle Scholar
  15. Flowers CM, Racoosin JA, Lu SL, Beitz JG (2003) The US Food and Drug Administration’s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730–731PubMedCrossRefGoogle Scholar
  16. Grosset K, Needleman F, Macphee G, Grosset D (2004) Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov Disord 19:1370–1374PubMedCrossRefGoogle Scholar
  17. Hendrikx M, Van Dorpe J, Flameng W, Daenen W (1996) Aortic and mitral valve disease induced by ergotamine therapy for migraine: a case report and review of the literature. J Heart Valve Dis 5:235–237PubMedGoogle Scholar
  18. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K et al (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053PubMedCrossRefGoogle Scholar
  19. Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S et al (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656–662PubMedCrossRefGoogle Scholar
  20. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T (2000) Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101:2071–2077PubMedGoogle Scholar
  21. Junghanns S, Fuhrmann JT, Simonis G, Oelwein C, Koch R, Strasser RH et al (2007) Valvular heart disease in Parkinson’s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord 22:234–238PubMedCrossRefGoogle Scholar
  22. Kenangil G, Ozekmekci S, Koldas L, Sahin T, Erginoz E (2007) Assessment of valvulopathy in Parkinson’s disease patients on pergolide and/or cabergoline. Clin Neurol Neurosurg 109:350–353PubMedCrossRefGoogle Scholar
  23. Kim JY, Chung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson’s disease treated with ergot derivative dopamine agonists. Mov Disord 21:1261–1264PubMedCrossRefGoogle Scholar
  24. Lieberman A, Ranhosky A, Korts D (1997) Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49:162–168PubMedCrossRefGoogle Scholar
  25. Lieberman A, Olanow CW, Sethi K, Swanson P, Waters CH, Fahn S et al (1998) A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Ropinirole Study Group. Neurology 51:1057–1062PubMedGoogle Scholar
  26. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson’s disease. Lancet 1:345–349PubMedCrossRefGoogle Scholar
  27. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303:791–804PubMedCrossRefGoogle Scholar
  28. Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58:11–17PubMedCrossRefGoogle Scholar
  29. Mizuno Y, Yanagisawa N, Kuno S, Yamamoto M, Hasegawa K, Origasa H et al (2003) Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Disord 18:1149–1156PubMedCrossRefGoogle Scholar
  30. Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verriele L, Carpentier N et al (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 303:815–822PubMedCrossRefGoogle Scholar
  31. Nutt JG (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40:340–345PubMedCrossRefGoogle Scholar
  32. Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G et al (1989) Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39:11–19PubMedCrossRefGoogle Scholar
  33. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H et al (2006) Practice parameter: treatment of Parkinson’s disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:983–995PubMedCrossRefGoogle Scholar
  34. Peralta C, Wolf E, Alber H, Seppi K, Muller S, Bosch S et al (2006) Valvular heart disease in Parkinson’s disease vs. controls: an echocardiographic study. Mov Disord 21:1109–1113PubMedCrossRefGoogle Scholar
  35. Pinero A, Marcos-Alberca P, Fortes J (2005) Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353:1976–1977PubMedCrossRefGoogle Scholar
  36. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280–1286PubMedCrossRefGoogle Scholar
  37. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484–1491PubMedCrossRefGoogle Scholar
  38. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ (1992) Valve disease associated with ergot alkaloid use: echocardiographic and pathologic correlations. Ann Intern Med 117:50–52PubMedGoogle Scholar
  39. Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J (2007) Low incidence of restrictive valvulopathy in patients with Parkinson’s disease on moderate dose of pergolide. J Neurol 254:1575–1578PubMedCrossRefGoogle Scholar
  40. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38PubMedCrossRefGoogle Scholar
  41. Schwarz J (2003) Rationale for dopamine agonist use as monotherapy in Parkinson’s disease. Curr Opin Neurol 16(Suppl 1):S27–S33PubMedCrossRefGoogle Scholar
  42. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334–336PubMedCrossRefGoogle Scholar
  43. Shively BK, Roldan CA, Gill EA, Najarian T, Loar SB (1999) Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine. Circulation 100:2161–2167PubMedGoogle Scholar
  44. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL et al (1999) Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83:897–902PubMedCrossRefGoogle Scholar
  45. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008–2012PubMedCrossRefGoogle Scholar
  46. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D (2003) Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology 61:859–861PubMedGoogle Scholar
  47. Van Camp G, Flamez A, Cosyns B, Weytjens C, Muyldermans L, Van Zandijcke M et al (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183PubMedCrossRefGoogle Scholar
  48. Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016–1020PubMedCrossRefGoogle Scholar
  49. Wilke A, Hesse H, Hufnagel G, Maisch B (1997) Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J 18:701PubMedGoogle Scholar
  50. Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225–1229PubMedCrossRefGoogle Scholar
  51. Yamashiro K, Komine-Kobayashi M, Hatano T, Urabe T, Mochizuki H, Hattori N et al (2008) The frequency of cardiac valvular regurgitation in Parkinson’s disease. Mov Disord 23:935–941PubMedCrossRefGoogle Scholar
  52. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46PubMedCrossRefGoogle Scholar
  53. Zoghbi WA, Enriquez-Sarano M, Foster E, Grayburn PA, Kraft CD, Levine RA et al (2003) Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777–802PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Malcolm Steiger
    • 1
  • W. Jost
    • 2
  • F. Grandas
    • 3
  • G. Van Camp
    • 4
  1. 1.The Walton Centre for Neurology and NeurosurgeryLiverpoolUK
  2. 2.Department of NeurologyGerman Diagnostic ClinicWiesbadenGermany
  3. 3.Department of NeurologyHospital Gregorio MarañónMadridSpain
  4. 4.Academic HospitalBrusselsBelgium

Personalised recommendations